- Home
- CISS vs VRAX Comparison
CISS vs VRAX Comparison
Compare CISS & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- VRAX
- Stock Information
- Founded
- CISS 2022
- VRAX 2013
- Country
- CISS Greece
- VRAX United Kingdom
- Employees
- CISS N/A
- VRAX N/A
- Industry
- CISS Marine Transportation
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CISS Consumer Discretionary
- VRAX Health Care
- Exchange
- CISS Nasdaq
- VRAX Nasdaq
- Market Cap
- CISS 8.1M
- VRAX 7.8M
- IPO Year
- CISS N/A
- VRAX 2022
- Fundamental
- Price
- CISS $0.64
- VRAX $2.37
- Analyst Decision
- CISS
- VRAX
- Analyst Count
- CISS 0
- VRAX 0
- Target Price
- CISS N/A
- VRAX N/A
- AVG Volume (30 Days)
- CISS 253.9K
- VRAX 198.4K
- Earning Date
- CISS 11-18-2024
- VRAX 02-05-2025
- Dividend Yield
- CISS N/A
- VRAX N/A
- EPS Growth
- CISS N/A
- VRAX N/A
- EPS
- CISS N/A
- VRAX N/A
- Revenue
- CISS $46,661,732.00
- VRAX $84,872.00
- Revenue This Year
- CISS N/A
- VRAX $5,169.18
- Revenue Next Year
- CISS N/A
- VRAX $66.97
- P/E Ratio
- CISS N/A
- VRAX N/A
- Revenue Growth
- CISS 491.48
- VRAX 7.03
- 52 Week Low
- CISS $0.61
- VRAX $0.60
- 52 Week High
- CISS $68.50
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- CISS 24.09
- VRAX 64.60
- Support Level
- CISS $0.67
- VRAX $1.51
- Resistance Level
- CISS $0.78
- VRAX $1.98
- Average True Range (ATR)
- CISS 0.05
- VRAX 0.18
- MACD
- CISS 0.00
- VRAX 0.03
- Stochastic Oscillator
- CISS 1.48
- VRAX 98.85
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.